Cogent Biosciences is a publicly traded biotechnology company dedicated to developing innovative solutions for genetically driven diseases. With a strong emphasis on rational drug discovery and development, Cogent is advancing precision therapies that target the underlying causes of diseases, offering hope to patients. The company's lead candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor aimed at treating Systemic Mastocytosis and advanced gastrointestinal stromal tumors. Cogent fosters a collaborative and transparent work environment, where team members are encouraged to contribute to the company's vision of discovering and commercializing best-in-class therapies.